Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $2.03B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.03M
Average 1.23M
IMNM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Immunome, Inc.NASDAQ: IMNM
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$90.36M, compared with -$56.72M a year earlier. Trailing-twelve-month EBITDA was -$284.54M.
Context
- EBITDA amounted to 3017.4% of revenue in FY2025, up 1343.3 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$219.26M (-4.7%) for the fiscal year ending Dec 2026, a step up from the -38.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$90.36M-25.6% QoQ
- Last fiscal yearDec 2025
- -$209.44M-38.4% YoY
- LTMSep 2026
- -$284.54M-45.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.3% | -17.6% | +41.7 pp |
| 1 year | -38.4% | -4.7% | +33.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (209.44M) USD
- Year-over-year change
- -38.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (209.44M) | -38.4% |
| FY2024 | 2024-12-31 | (151.35M) | -440.6% |
| FY2023 | 2023-12-31 | (28M) | +22.8% |
| FY2022 | 2022-12-31 | (36.26M) | -51.4% |
| FY2021 | 2021-12-31 | (23.95M) | — |
EBITDA vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.7% is the 8th highest of 11, against a peer median of -10.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.24M USD | +2711.1% | — | 1.6% | |
| LTM Mar 2026 | -$34.56M USD | -66.8% | — | — | |
| LTM Sep 2026 | -$35.76M USD | -89.6% | — | — | |
| LTM Mar 2026 | -$42.27M USD | -2.3% | — | — | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$106.12M USD | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$145.24M USD | -14.0% | — | — | |
| LTM Mar 2026 | -€202.4M EUR | -4407.9% | — | 542.7% | |
| LTM Mar 2026 | -$211.5M USD | -0.8% | — | 333.1% | |
| LTM Sep 2026 | -$284.54M USD | -45.7% | — | — | |
| LTM Sep 2026 | -$305.37M USD | -38.1% | — | 272652.7% | |
| Peer median (excluding IMNM) | — | -10.5% | — | 219.8% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$17.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.